ALERT Communities Act
Key claim: The ALERT Communities Act expands SAMHSA first-responder grants to include rapid test strips for fentanyl, xylazine and other synthetic opioids and directs HHS to issue manufacturer guidance and study the strips’ effect on overdoses and treatment uptake.
Abstract
(HR1561 · 119th Congress) Advancing Lifesaving Efforts with Rapid Test strips for Communities Act or the ALERT Communities Act This bill establishes programs and requirements to advance the development and usage of test strips that detect the presence of certain hazardous drugs (e.g., fentanyl, xylazine). Currently, the Substance Abuse and Mental Health Services Administration provides grants to government entities to train and provide authorized equipment to first responders and other relevant personnel for emergency treatment of opioid overdoses. The bill expands these grants to include rapid response test strips for detecting the presence of fentanyl, xylazine, and other synthetic opioids or emerging substances in people or within other drugs. Additionally, the bill requires the Department of Health and Human Services (HHS) to publish guidance and standards for test strip manufacturers to support the development, evaluation, and authorization of test strips. Also, HHS must conduct a study and report to Congress on how the availability and usage of test strips and similar equipment impacts the frequency of overdoses and participation in substance use disorder treatment. Latest action (2026-07-21): Ordered to be Reported by the Yeas and Nays: 48 - 0.
Why this matters
Fentanyl and xylazine test strips have historically sat in a legal gray zone as drug paraphernalia in many jurisdictions; explicitly authorizing SAMHSA first-responder grants to purchase them would federalize this harm-reduction tool alongside naloxone. The directive for HHS manufacturer guidance and an impact study could standardize product quality and generate the first federal evidence base on whether test-strip distribution reduces overdoses or increases treatment engagement.